Addrena LLC – Trademark Portfolio

Entity Type: 16

Addrena LLC holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 9 filings in this category. Currently, 5 trademarks are registered. Notable registered marks include ADRELI, ADDRENA, ACNETAME, ESTROHALT, and FOCUS PEP. The owner is based in Port Charlotte, FL.

2200 Kings HWY #159

2200 Kings HWY #159

Port Charlotte, FL 33980

9 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ADRELI
ADRELI
Registered 2024
ADDREL
ADDREL
Abandoned 2023
ADIBRAND
ADIBRAND
Abandoned 2023
ESTROHALT
ESTROHALT
Registered 2018
NO STIM
NO STIM
Abandoned 2018
FOCUS PEP
FOCUS PEP
Registered 2018
ADDRENA
ADDRENA
Registered 2015
ACNETAME
ACNETAME
Registered 2015

Trademark Classifications

Addrena LLC's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (9 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Addrena LLC have?

Addrena LLC has 9 U.S. trademarks filed with the USPTO. Of these, 5 registered, 4 abandoned.

What trademark classes does Addrena LLC file in?

Addrena LLC files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Addrena LLC's most well-known trademarks?

Addrena LLC's registered trademark portfolio includes well-known marks such as ADRELI, ADDRENA, ACNETAME, ESTROHALT, and FOCUS PEP. These are among 5 currently registered trademarks in the portfolio.

What is Addrena LLC's trademark registration success rate?

Addrena LLC has a 56% trademark registration rate, with 5 out of 9 resolved applications resulting in successful registration. Currently, 0 applications are pending review.